Literature DB >> 17012622

Short polybasic peptide sequences are potent inhibitors of PC5/6 and PC7: Use of positional scanning-synthetic peptide combinatorial libraries as a tool for the optimization of inhibitory sequences.

Martin Fugere1, Jon Appel, Richard A Houghten, Iris Lindberg, Robert Day.   

Abstract

Positional scanning-synthetic peptide combinatorial libraries (PS-SPCLs) are powerful molecular tools to identify enzyme substrate and potent inhibitory sequences and also to provide crucial information about active site determinants. PS-SPCLs have been surveyed for furin, proprotein convertase (PC)2, PC1/3, and PACE4 and proven efficient to identify potent peptidyl inhibitors in the low nanomolar range for furin and PC1/3. We report herein the screenings of nonamidated and acetylated hexapeptide PS-SPCLs for PC5/6A and PC7. The L-configuration library surveys distinctively revealed that L-Arg, L-Lys, and sometimes L-His in all six positions would generate the most potent inhibitors for both enzymes. Based on this clear polybasic preference, L-poly-Arg peptides ranging from four to nine residues were assayed. Inhibitory potency of these polybasic peptides increased with chain length, making nona-l-Arg a potent nanomolar inhibitor of PC5/6A and PC7 (Ki of 150 and 120 nM). PC5/6 and PC7 inhibition by nona-l-arginine was equivalent to that of furin (Ki of 114 nM) (J Biol Chem 275: 36741-36749, 2000). Nona-d-arginine was a more potent inhibitor of PC5/6 and PC7 than its levorotatory version (Ki of 19 and 81 nM), reminiscent of furin (Ki of 1.3 nM) (J Biol Chem 279:36788-36794, 2004). Our data indicate that certain poly-arginine peptides represent potent inhibitors targeting PCs of the constitutive secretory pathway (furin, PC5/6, and PC7). We conclude that basic residues within PC peptide inhibitors might be responsible for targeting PCs in general and for inhibitory potency, but that select amino acid changes will be necessary to acquire true specificity toward a single PC.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17012622     DOI: 10.1124/mol.106.027946

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  21 in total

1.  The proprotein convertase PC7: unique zymogen activation and trafficking pathways.

Authors:  Estelle Rousselet; Suzanne Benjannet; Josée Hamelin; Maryssa Canuel; Nabil G Seidah
Journal:  J Biol Chem       Date:  2010-11-12       Impact factor: 5.157

2.  On the cutting edge of proprotein convertase pharmacology: from molecular concepts to clinical applications.

Authors:  Frédéric Couture; François D'Anjou; Robert Day
Journal:  Biomol Concepts       Date:  2011-10-01

Review 3.  As the world grows: contraception in the 21st century.

Authors:  R John Aitken; Mark A Baker; Gustavo F Doncel; Martin M Matzuk; Christine K Mauck; Michael J K Harper
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

4.  Identification of potent and compartment-selective small molecule furin inhibitors using cell-based assays.

Authors:  Bruno Ramos-Molina; Adam N Lick; Elias H Blanco; J Alejandro Posada-Salgado; Karina Martinez-Mayorga; Alan T Johnson; Guan-Sheng Jiao; Iris Lindberg
Journal:  Biochem Pharmacol       Date:  2015-05-21       Impact factor: 5.858

5.  Proprotein convertase PC7 enhances the activation of the EGF receptor pathway through processing of the EGF precursor.

Authors:  Estelle Rousselet; Suzanne Benjannet; Edwidge Marcinkiewicz; Marie-Claude Asselin; Claude Lazure; Nabil G Seidah
Journal:  J Biol Chem       Date:  2011-01-05       Impact factor: 5.157

Review 6.  Proprotein convertase inhibition: Paralyzing the cell's master switches.

Authors:  Andres J Klein-Szanto; Daniel E Bassi
Journal:  Biochem Pharmacol       Date:  2017-04-27       Impact factor: 5.858

7.  Generation and characterization of non-competitive furin-inhibiting nanobodies.

Authors:  Jingjing Zhu; Jeroen Declercq; Bart Roucourt; Gholamreza H Ghassabeh; Sandra Meulemans; Jörg Kinne; Guido David; Alphons J M Vermorken; Wim J M Van de Ven; Iris Lindberg; Serge Muyldermans; John W M Creemers
Journal:  Biochem J       Date:  2012-11-15       Impact factor: 3.857

8.  Assessment of recombinant tissue plasminogen activator (rtPA) toxicity in cultured neural cells and subsequent treatment with poly-arginine peptide R18D.

Authors:  Jade E Kenna; Ryan S Anderton; Neville W Knuckey; Bruno P Meloni
Journal:  Neurochem Res       Date:  2020-03-05       Impact factor: 3.996

9.  A novel enediynyl peptide inhibitor of furin that blocks processing of proPDGF-A, B and proVEGF-C.

Authors:  Ajoy Basak; Abdel-Majid Khatib; Dayani Mohottalage; Sarmistha Basak; Maria Kolajova; Subhendu Sekhar Bag; Amit Basak
Journal:  PLoS One       Date:  2009-11-26       Impact factor: 3.240

10.  The Multi-Leu peptide inhibitor discriminates between PACE4 and furin and exhibits antiproliferative effects on prostate cancer cells.

Authors:  Christine Levesque; Martin Fugère; Anna Kwiatkowska; Frédéric Couture; Roxane Desjardins; Sophie Routhier; Philippe Moussette; Adam Prahl; Bernard Lammek; Jon R Appel; Richard A Houghten; François D'Anjou; Yves L Dory; Witold Neugebauer; Robert Day
Journal:  J Med Chem       Date:  2012-11-14       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.